Novo Nordisk Wegovy Data Challenges Foundayo And Resets Valuation Debate [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Novo Nordisk released new cross trial data indicating its oral Wegovy pill produces greater weight loss than Eli Lilly's newly FDA approved obesity pill Foundayo. The company reports fewer adverse events with Wegovy compared with Foundayo and cites strong patient preference for Wegovy's treatment profile. This is the first direct comparison between the two oral GLP 1 obesity treatments as Eli Lilly prepares to launch Foundayo in the United States. For investors watching CPSE:NOVO B, this data arrives at a time when Novo Nordisk's share price stands at DKK236.9 and longer term returns have been mixed. The stock is up 3.7% over the past week, the 1 year return shows a 42.6% decline, and the 5 year return sits at 20.2%. Those swings underline how sensitive sentiment has been to developments in the obesity drug space. The fresh Wegovy data sets up a head to head contest in oral GLP 1 treatments that could shape how physicians and patients think about efficacy and tolerability. As
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk (NVO) Increases Yet Falls Behind Market: What Investors Need to Know [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S (NVO) was upgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (d+)" to "hold (c-)".MarketBeat
- Which of These Healthcare Stocks Is More Likely to Be a Millionaire Maker? [Yahoo! Finance]Yahoo! Finance
- CNBC's UK Exchange newsletter: Brace yourself for rising bills as new tax year kicks off Share [CNBC]CNBC
- Vltava Fund Q1 2026 Letter To Shareholders [Seeking Alpha]Seeking Alpha
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/7/26 - Form 6-K
- 3/30/26 - Form 6-K
- 3/27/26 - Form 6-K
- NVO's page on the SEC website